Cinrebafusp alfa (PRS-343) in combination with ramucirumab and paclitaxel for Gastric Cancer

Phase 2

Waitlist Available

Research Sponsored by Pieris Pharmaceuticals, Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

No Placebo-Only Group

Summary

This trial tests a new treatment called cinrebafusp alfa combined with other cancer drugs in patients with stomach or GEJ cancer. It targets a protein called HER2 to help the immune system destroy cancer cells.

Eligible Conditions

HER2 Positive Gastric Cancer

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Group I: Cinrebafusp alfa (PRS-343) in combination with tucatinibExperimental Treatment1 Intervention

Patients aged 18 years or older with HER2 low (IHC 1+ or IHC 2+ without HER2/neu amplification) gastric or GEJ adenocarcinoma who have received at least one prior treatment regimen

Group II: Cinrebafusp alfa (PRS-343) in combination with ramucirumab and paclitaxelExperimental Treatment1 Intervention

Patients aged 18 years or older with HER2-positive gastric or GEJ adenocarcinoma who have progressed on prior treatment with a regimen containing a platinum and fluoropyrimidine and a HER2-directed therapy such as trastuzumab and now are candidates for treatment with ramucirumab and paclitaxel

Do I qualify?Apply below to find out